We are live on ! Find out more
BRTX icon

BioRestorative Therapies
BRTX

9 hedge funds and large institutions have $184K invested in BioRestorative Therapies in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.03% less ownership

Funds ownership: 3.69% → 2.66% (-1%)

25% less funds holding

Funds holding: 12 → 9 (-3)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

52% less capital invested

Capital invested by funds: $383K → $184K (-$199K)

Holders
9
Holders Change
-3
Holders Change %
-25%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$134K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$106K
3
UBS Group
UBS Group
Switzerland
+$64.1K
4
TRCT
Tower Research Capital (TRC)
New York
+$231
5
SS
SBI Securities
Japan
+$51

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$54.8K
2
NF
Napier Financial
Massachusetts
-$20.1K
3
TSS
Two Sigma Securities
New York
-$13.8K
4
Bank of America
Bank of America
North Carolina
-$71

BRTX Hedge Fund Activity: Q1 2026 in Review

9 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2026, worth a combined $184K — down 52% from $383K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BRTX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 4 added.

The largest buyer was Citadel Advisors, adding an estimated $134K. The largest seller was DRW Securities, exiting entirely with an estimated $54.8K sold.

  • 9 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2026, down from 12 in Q4 2025.
  • Funds reported $184K of BioRestorative Therapies stock for Q1 2026, down 52% quarter-over-quarter.
  • 2 funds opened new BioRestorative Therapies positions in Q1 2026 and 4 closed out, a net change of -2 holders.
  • The largest BioRestorative Therapies buyer in Q1 2026 was Citadel Advisors, an estimated $134K added.
  • The largest BioRestorative Therapies seller in Q1 2026 was DRW Securities, an estimated $54.8K sold.

Based on aggregated 13F filings for Q1 2026.